rinatabart sesutecan
Sponsor Genmab A/S · listed as GMAB
rinatabart sesutecan is a drug asset sponsored by Genmab A/S, listed as GMAB. CSA tracks 1 forward catalyst for it — the nearest is a readout expected Sep 2027 (month precision, medium confidence), tied to trial NCT07604766. That trial is in Phase 3 and currently recruiting, studying Platinum-resistant Ovarian Cancer. It appears across 6 tracked trials in the CSA sample.
Next catalyst
Trial & sponsor
Trials for rinatabart sesutecan in the CSA sample
| Trial | Phase | Status | Primary completion | Role | Lead sponsor | Condition(s) |
|---|---|---|---|---|---|---|
| NCT06619236 | Phase 3 | Active, not recruiting | 2026-08-18 | Experimental | Genmab | Platinum-resistant Ovarian Cancer |
| NCT07604766 catalyst | Phase 3 | Recruiting | 2027-09 | Experimental | Genmab | Platinum-resistant Ovarian Cancer |
| NCT07225270 | Phase 3 | Recruiting | 2028-10 | Experimental | Genmab | Ovarian Cancer; Platinum-sensitive Ovarian Cancer; PSOC |
| NCT07166094 | Phase 3 | Recruiting | 2029-08 | Experimental | Genmab | Endometrial Cancer; Recurrent or Progressive Endometrial Cancer |
| NCT07564141 | Phase 3 | Recruiting | 2029-12 | Experimental | Genmab | Platinum-Sensitive Ovarian Cancer; Ovarian Cancer |
| NCT07859215 | Phase 3 | Not yet recruiting | 2030-03 | Experimental | Genmab | Ovarian Cancer |
Each trial links to its ClinicalTrials.gov record; primary completion dates are as registered there.
Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.
This page is one record from the free CSA sample. The full snapshot covers active, industry-sponsored Phase 3 trials in cardiometabolic, oncology and immunology. Every forward catalyst carries its date, confidence grade and source link, and is linked to its sponsor's ticker when the sponsor is a listed company.
Get the full dataset — $499 → More GMAB catalysts